WRN Promoter CpG Island Hypermethylation Does Not Predict a Favourable Outcome for Irinotecan-treated Metastatic Colorectal Cancer Patients

被引：0
|
作者：
Bosch, L. J. W. [1 ]
Luo, Y. [2 ]
Lao, V. V. [3 ]
Snaebjornsson, P. [1 ]
Trooskens, G. [4 ]
Vlassenbroeck, I. [5 ]
Mongera, S. [1 ]
Tang, W. [3 ]
Welcsh, P. [3 ]
Herman, J. [6 ]
Koopman, M. [7 ]
Nagtegaal, I. [8 ]
Punt, C. J. A. [9 ]
van Criekinge, W. [4 ]
Meijer, G. A. [1 ]
Monnat, R. J. [3 ]
Carvalho, B. [1 ]
Grady, W. M. [3 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[2] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou 510275, Guangdong, Peoples R China
[3] Univ Washington, Seattle, WA 98195 USA
[4] Univ Ghent, B-9000 Ghent, Belgium
[5] MDxHealth SA, Liege, Belgium
[6] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[7] Univ Med Ctr Utrecht, Nijmegen, Netherlands
[8] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[9] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
来源：
JOURNAL OF PATHOLOGY | 2015年 / 237卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [41] Lack of Association of Proteinuria and Clinical Outcome in Patients Treated with Bevacizumab for Metastatic Colorectal Cancer
    Iwasa, Satoru
    Nakajima, Takako Eguchi
    Nagashima, Kengo
    Honma, Yoshitaka
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2013, 33 (01) : 309 - 316
  • [42] Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX
    Dae-Won Lee
    Sae-Won Han
    Yongjun Cha
    Ye Young Rhee
    Jeong Mo Bae
    Nam-Yun Cho
    Kyung-Hun Lee
    Tae-Yong Kim
    Do-Youn Oh
    Seock-Ah Im
    Yung-Jue Bang
    Seung-Yong Jeong
    Kyu Joo Park
    Gyeong Hoon Kang
    Tae-You Kim
    Clinical Epigenetics, 2015, 7
  • [43] Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX
    Lee, Dae-Won
    Han, Sae-Won
    Cha, Yongjun
    Rhee, Ye Young
    Bae, Jeong Mo
    Cho, Nam-Yun
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Oh, Do-Youn
    Im, Seock-Ah
    Bang, Yung-Jue
    Jeong, Seung-Yong
    Park, Kyu Joo
    Kang, Gyeong Hoon
    Kim, Tae-You
    CLINICAL EPIGENETICS, 2015, 7
  • [44] ABCC2 Genotype is a Biomarker of Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with FOLFIRI
    Nagashima, Fumio
    Fujita, Ken-ichi
    Yamashita, Keishi
    Yamamoto, Wataru
    Eodo, Hisashi
    Sunakawa, Yu
    Ishida, Hiroo
    Mizuno, Keiko
    Matsunaga, Mototsugu
    Araki, Kazuhiro
    Tanaka, Ryuhei
    Ichikawa, Wataru
    Miya, Toshimichi
    Narabayashi, Masaru
    Akiyama, Yuko
    Kawara, Kaori
    Ando, Yuichi
    Sasaki, Yasutsuna
    TUMOR BIOLOGY, 2008, 29 : 85 - 85
  • [45] Retrospective analysis of patients treated with cetuximab plus FOLFIRI for previous irinotecan combined chemotherapy in metastatic colorectal cancer
    Woo, Jae P.
    Eun-joo, J.
    Sun-mi, M.
    Dae-yong, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 95 - 95
  • [46] Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan
    Palshof, Jesper Andreas
    Christensen, Troels Dreier
    Poulsen, Tim Svendstrup
    Jensen, Benny Vittrup
    Linnemann, Dorte
    Schou, Jakob Vasehus
    Pfeiffer, Per
    Yilmaz, Mette K. N.
    Christensen, Ib Jarle
    Hogdall, Estrid V.
    Nielsen, Dorte
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Clinical mucositis and intestinal permeability abnormalities in metastatic colorectal cancer patients treated with irinotecan and 5-fluoruracil.
    Gifoni, Markus
    Lima, Roberto Cesar
    Moreira Lima, Aldo Angelo
    Facanha, Adriana
    Callado, Rodrigo Barbosa
    Azevedo, Carolina
    Ribeiro, Ronaldo De Albuquerque
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab plus Irinotecan
    Bando, Hideaki
    Yoshino, Takayuki
    Yuki, Satoshi
    Shinozaki, Eiji
    Nishina, Tomohiro
    Kadowaki, Shigenori
    Yamazaki, Kentaro
    Kajiura, Shinya
    Tsuchihara, Katsuya
    Fujii, Satoshi
    Yamanaka, Takeharu
    Ohtsu, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (12) : 1146 - 1151
  • [49] Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
    Bibeau, Frederic
    Lopez-Crapez, Evelyne
    Di Fiore, Frederic
    Thezenas, Simon
    Ychou, Marc
    Blanchard, France
    Lamy, Aude
    Penault-Llorca, Frederique
    Frebourg, Thierry
    Michel, Pierre
    Sabourin, Jean-Christophe
    Boissiere-Michot, Florence
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) : 1122 - 1129
  • [50] Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status
    Fornaro, Lorenzo
    Baldi, Giacomo Giulio
    Masi, Gianluca
    Allegrini, Giacomo
    Loupakis, Fotios
    Vasile, Enrico
    Cupini, Samanta
    Stasi, Irene
    Salvatore, Lisa
    Cremolini, Chiara
    Vincenzi, Bruno
    Santini, Daniele
    Tonini, Giuseppe
    Graziano, Francesco
    Ruzzo, Annamaria
    Canestrari, Emanuele
    Magnani, Mauro
    Falcone, Alfredo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (03) : 243 - 251
12345